Motor Neurone Disease (MND) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Motor Neurone Disease (MND) is also known as Amyotrophic lateral sclerosis (ALS). It is a debilitating, fatal, late-onset degenerative disorder of the nervous system characterized by motor neuron degeneration, which leads to progressive muscle wasting and weakness. The disease progresses rapidly; the median survival is three to five years, and only 20% of patients are alive five to ten years after symptom onset. Death usually results from respiratory failure. Despite the poor prognosis, there is considerable variation in the survival rate, and up to 10% of people with ALS live for more than eight years from the onset of the first symptoms. The significant breakthroughs in the etiology and pathophysiology of ALS are the discovery of various genetic risk factors such as mutations in SOD1, TARDBP, FUS, C9orf72, TBK1, and NEK1. Most of these risk factors were discovered only within the last ten years, and extensive research is underway to uncover the common mechanisms affected by these mutations that may lead to ALS, such as protein misfolding and aggregation.

·       ALS prevalence in the United States ranges between 5.2 to 6.5 cases per 100,000 population, whereas incidence cases range between o.6 to 2.8 cases per 100,000 population.

Thelansis’s “Motor Neurone Disease (MND) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Motor Neurone Disease (MND) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Motor Neurone Disease (MND) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Motor Neurone Disease (MND) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Motor Neurone Disease (MND) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032